Sign in
CompletedNo phase

PNEUmonia DOSing in Critically Ill Patients (PNEUDOS)

Key facts

Who runs it
The University of Queensland
Where
Australia, Belgium, France, Hong Kong, and Malaysia6 sites in 5 countriesChoose a country to see its sites
Trial code
Status
Completed
People taking part
179 people enrolled
Started
17 Oct 2019
Ended
31 Jan 2024
Type of study
Observational, 4 groups
Treatments tested
  • Blood sampling
  • Epithelial lining fluid sampling
  • Urine sampling
  • Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam
Record updated
28 January 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Adult (≥18 years old) ICU patients
  • Confirmed or suspected either community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically diagnosed lung infection
  • Patient has been prescribed or is receiving one of the study drugs (benzylpenicillin, ceftriaxone, meropenem, or piperacillin/tazobactam) for the treatment of pneumonia in the ICU
  • Patient is sedated and receiving mechanical ventilation
  • Patient has arterial line and urinary catheter in situ for blood and urine samplings
  • Informed consent to participate in the study

Who cannot take part

  • Receiving renal replacement therapy (RRT)
  • Has received study antibiotic for more than 72 hours (at time of Occasion 1) during current infective episode
  • Suspected or known hypersensitivity towards beta-lactam antibiotics (pre- or post-enrolment)
  • Pregnant patients or lactating mothers

This trial has no sites in United States.

It has sites in 5 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Pneumonia is the most common infection in intensive care unit (ICU) patients and occurs in 10% of all ICU admissions. Unfortunately, ICU patient outcomes remain poor with a high mortality rate associated with pneumonia despite recent therapeutic advances.

Read full original descriptionShow less

Previous studies of antibiotics used in ICU patients, which includes ceftriaxone, meropenem and piperacillin/tazobactam, have quantified major differences in pharmacokinetics (PK) between ICU and non-ICU patients, with ICU patients displaying a unique spectrum of plasma concentration-time profiles. These PK differences can lead to suboptimal antibiotic concentrations in blood, which have been associated with a reduced likelihood of clinical cure for pneumonia. Furthermore, highlighting the importance of optimised dosing for pneumonia is that multi-drug resistant (MDR) pathogens emerge during antibiotic therapy in approximately half of the ICU patients, frequently emerging from the lung.

Previous work has highlighted how infection site concentrations determine patient outcome. For pneumonia, the infection site is best described as the epithelial lining fluid (ELF) in the lung.

Although optimal antibiotic therapy should be considered a priority for ICU patients with pneumonia to improve the persisting poor outcomes, the dosing regimens that can achieve therapeutic concentrations at the infection site (i.e., ELF) in ICU patients with pneumonia remain unknown.

The PNEUDOS study aims to address this significant knowledge gap by defining novel individualised dosing regimens that can maximise antibiotic efficacy by achieving therapeutic concentrations in the blood and ELF of ICU patients with pneumonia. These dosing regimens can then be validated in future clinical trials.

The 4 groups in the trial

  • Benzylpenicillin

    ICU patients receiving benzylpenicillin for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)

    Treatment: Blood sampling, Epithelial lining fluid sampling, Urine sampling, and Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam

  • Ceftriaxone

    ICU patients receiving ceftriaxone for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)

    Treatment: Blood sampling, Epithelial lining fluid sampling, Urine sampling, and Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam

  • Meropenem

    ICU patients receiving meropenem for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)

    Treatment: Blood sampling, Epithelial lining fluid sampling, Urine sampling, and Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam

  • Piperacillin/tazobactam

    ICU patients receiving piperacillin/tazobactam for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)

    Treatment: Blood sampling, Epithelial lining fluid sampling, Urine sampling, and Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-centre Study to Define Novel Individualised Dosing Regimens to Maximise Antibiotic Effectiveness for Treatment of Pneumonia in Intensive Care Units
Record updated
28 January 2026